臨床外科70巻5号

2015年05月発行

特集 外科医が知っておくべき がん薬物療法の副作用とその対策

症状別対策マニュアル

心毒性

著者： 秋吉清百合¹ 大野真司¹

所属機関： ¹国立病院機構九州がんセンター乳腺科

ページ範囲：P.599 - P.602

文献概要

【ポイント】
◆アントラサイクリン系薬剤には，非可逆性の蓄積性心毒性があるため，総投与量と定期的心機能評価が重要である．
◆トラスツズマブによる左室機能障害は可逆性であり，定期的な心機能評価を行い，休薬，再開を駆使する必要がある．
◆化学療法開始前，治療中，治療終了後における心機能評価と自覚症状のチェックが重要である．

参考文献

1）Curigliano G, Cardinale D, Suter T, et al：Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy：ESMO Clinical Practice Guidelines. Ann Oncol 23 （Suppl 7）：vii155-166, 2012

2）Todaro MC, Oreto L, Qamar R, et al：Cardioncology：State of the heart. Int J Cardiol 168：680-687, 2013

3）Von Hoff DD, Layard MW, Basa P, et al：Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91：710-717, 1979

4）Carver JR, Shapiro CL, Ng A, et al：American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors：cardiac and pulmonary late effects. J Clin Oncol 25：3991-4008, 2007

5）Alter P, Herzum M, Soufi M, et al：Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 4：1-5, 2006

6）Slamon DJ, Leyland-Jones B, Shak S, et al：Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344：783-792, 2001

7）Tan-Chiu E, Yothers G, Romond E, et al：Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2 - overexpressing breast cancer：NSABP B-31. J Clin Oncol 23：7811-7819, 2005

8）Hudis CA：Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357：39-51, 2007

9）Wang L, Proud CG：Ras/Erk signaling is essential for activation of protein synthesis by Gp protein-coupled receptor agonists in adult cardiomyocytes. Circ Res 91：821-829, 2002

10）Sawyer DB, Zuppinger C, Miller TA, et al：Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2：potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105：1551-1554, 2002

11）Liu FF, Stone JR, Schuldt AJ, et al：Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 289：H660-666, 2005

12）Gabrielson K, Bedja D, Pin S, et al：Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 67：1436-1441, 2007

13）Guarneri V, Lenihan DJ, Valero V, et al：Long-term cardiac tolerability of trastuzumab in metastatic breast cancer：the M.D. Anderson Cancer Center experience. J Clin Oncol 24：4107-4115, 2006

14）Perez EA, Koehler M, Byrne J, et al：Cardiac safety of lapatinib：pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83：679-686, 2008